95 results
Page 4 of 5
8-K
EX-99.1
c5uh55
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
m7zyid3y8kq 801ou0k
15 Jun 20
Regulation FD Disclosure
7:21am
8-K
EX-1.1
3ch5m phgzj2pqdggu
12 May 20
Entry into a Material Definitive Agreement
5:14pm
424B5
77hhhozg4uczznz1r
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
dinz d5ca
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
2yiv5
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
1cgjd6k4
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.2
bnodzzmhvsy3q3n vne0
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
wnpfx6hs6fhwa wrad3h
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
xeflzoj7b j7pvm
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
mt1er 00w2t
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
5l8zyq zy
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.2
fuyc mpifsgb6m
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
ahit8fq3
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
bybvd
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
EX-1.2
6ce xx6rbtm1fywe
4 Oct 19
Shelf registration
4:06pm